Skip to main content
Year archive

Strategic Partners A/S — 2022 filings

All 46 regulatory filings released by Strategic Partners A/S (STRAP) in 2022, sourced directly from the official regulator.

46 Filings
2022 Period
2022 filings (46)
Filing Released Lang
Interim / Quarterly Report 2022
Interim / Quarterly Report H1 2022
2022-09-26 English
Orphazyme reports financial results in Interim Report First Half 2022
Interim / Quarterly Report H1 2022
2022-09-26 English
Orphazyme reports financial results in Interim Report First Half 2022
Report Publication Announcement H1 2022
2022-09-26 English
Regulatory Filings 2022
Regulatory Filings
2022-09-25 English
Adjusted financial outlook for 2022
Earnings Release FY 2022
2022-09-25 English
Annual Report 2021
Annual Report FY 2021
2022-06-08 English
Annual Report (ESEF) 2021
Annual Report (ESEF) FY 2021
2022-06-08 English
Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Report Publication Announcement FY 2021
2022-06-08 English
Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Report Publication Announcement
2022-06-08 English
Annual Report (ESEF) 2021
Annual Report (ESEF) FY 2021
2022-06-08 English
Report Publication Announcement 2022
Report Publication Announcement
2022-06-07 English
Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Annual Report FY 2021
2022-06-07 English
Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Report Publication Announcement FY 2021
2022-06-07 English
Delisting Announcement 2022
Delisting Announcement
2022-05-31 English
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
M&A Activity
2022-05-31 English
Legal Proceedings Report 2022
Legal Proceedings Report
2022-05-30 English
Restructuring proposal adopted by creditors
Regulatory Filings
2022-05-30 English
Legal Proceedings Report 2022
Legal Proceedings Report
2022-05-18 English
Restructuring Proposal
Regulatory Filings
2022-05-18 English
Restructuring Proposal
Report Publication Announcement
2022-05-18 English
Delisting Announcement 2022
Delisting Announcement
2022-05-15 English
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
M&A Activity
2022-05-15 English
Legal Proceedings Report 2022
Legal Proceedings Report
2022-04-29 English
Orphazyme announces update on in-court restructuring proceedings
M&A Activity
2022-04-29 English
Legal Proceedings Report 2022
Legal Proceedings Report
2022-04-07 English
Statutory restructuring plan adopted by creditors
Regulatory Filings
2022-04-07 Danish
Legal Proceedings Report 2022
Legal Proceedings Report
2022-04-04 English
Correction: Proposal for a statutory restructuring plan
Regulatory Filings
2022-04-04 English
Correction: Proposal for a statutory restructuring plan
Regulatory Filings
2022-04-04 Danish
Legal Proceedings Report 2022
Legal Proceedings Report
2022-03-31 English
Proposal for a statutory restructuring plan
Regulatory Filings
2022-03-31 English
Proposal for a statutory restructuring plan
Legal Proceedings Report
2022-03-31 English
Legal Proceedings Report 2022
Legal Proceedings Report
2022-03-22 English
Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C
Regulatory Filings
2022-03-22 Danish
Legal Proceedings Report 2022
Legal Proceedings Report
2022-03-10 English
Commencement of in-court restructuring of Orphazyme A/S
Regulatory Filings
2022-03-10 Danish
Board/Management Information 2022
Board/Management Information
2022-02-28 English
Anders Vadsholt takes over as CEO of Orphazyme
Board/Management Information
2022-02-28 English
Regulatory Filings 2022
Regulatory Filings
2022-02-23 English
Orphazyme announces update on regulatory review of arimoclomol in the European Union
Regulatory Filings
2022-02-23 Danish
Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program
Share Issue/Capital Change
2022-02-18 English
Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program
Share Issue/Capital Change
2022-02-18 English
Board/Management Information 2022
Board/Management Information
2022-01-31 English
Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO
Board/Management Information
2022-01-31 English
Earnings Release 2021
Earnings Release FY 2021
2022-01-18 English
Orphazyme updates 2021 financial outlook
Earnings Release FY 2021
2022-01-18 English